{"id":23906,"date":"2026-05-22T00:00:00","date_gmt":"2026-05-22T00:00:00","guid":{"rendered":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/"},"modified":"2026-05-22T00:00:00","modified_gmt":"2026-05-22T00:00:00","slug":"331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos","status":"publish","type":"post","link":"https:\/\/angelboss.com.br\/en\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/","title":{"rendered":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=be4b13655d0bf303c964e3eb5584d91e\" rel=\"follow\" shape=\"rect\" target=\"_blank\">BeOne Medicines Ltd.<\/a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje que mais de 60 resumos sobre neoplasias hematol\u00f3gicas e tumores s\u00f3lidos foram aceitos para apresenta\u00e7\u00e3o na Reuni\u00e3o Anual de 2026 da Sociedade Americana de Oncologia Cl\u00ednica (ASCO), que ocorrer\u00e1 entre 29 de maio e 2 de junho em Chicago, e no congresso de 2026 da Associa\u00e7\u00e3o Europeia de Hematologia (EHA), que ocorrer\u00e1 entre 11 e 14 de junho em Estocolmo.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Continuando a elevar o padr\u00e3o na LLC<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nNa ASCO e na EHA 2026, a BeOne demonstrar\u00e1 sua lideran\u00e7a em hematologia com dados que abrangem terapias fundamentais e inova\u00e7\u00f5es de \u00faltima gera\u00e7\u00e3o em LLC, linfoma de c\u00e9lulas do manto e outras neoplasias de c\u00e9lulas B. Os dados destacam resultados impressionantes a longo prazo, durabilidade em popula\u00e7\u00f5es de pacientes e uma abordagem disciplinada para o avan\u00e7o de regimes terap\u00eauticos futuros. Coletivamente, esses dados refor\u00e7am a estrat\u00e9gia da BeOne de liderar a ci\u00eancia hematol\u00f3gica e o impacto sobre os pacientes, estabelecendo o padr\u00e3o hoje \u2013 ao mesmo tempo em que ajuda a moldar o futuro da LLC.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Amit Agarwal, M.D., Ph.D., diretor m\u00e9dico de Hematologia da BeOne Medicines, afirmou:<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cOs dados de acompanhamento de 78 meses do SEQUOIA refor\u00e7am o que realmente \u00e9 necess\u00e1rio para liderar no tratamento da LLC no longo prazo: efic\u00e1cia duradoura, capacidade de sequenciar tratamentos e confian\u00e7a nas decis\u00f5es terap\u00eauticas de primeira linha. Com base nessa lideran\u00e7a, estamos entusiasmados em avan\u00e7ar rapidamente com a pr\u00f3xima gera\u00e7\u00e3o de medicamentos, incluindo combina\u00e7\u00f5es baseadas em sonrotoclax e nosso degradador de BTK BGB-16673, desenvolvidos para ampliar o que \u00e9 poss\u00edvel para os pacientes em diferentes linhas de tratamento.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>As principais apresenta\u00e7\u00f5es de dados em LLC incluem:<\/b><\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li>\nnovos resultados do <b>estudo SEQUOIA, com 78 meses de acompanhamento<\/b>, reafirmam o Brukinsa<sup>\u00ae<\/sup> (zanubrutinibe) como o inibidor de BTK mais importante para a LLC, proporcionando controle duradouro da doen\u00e7a e elevando as expectativas de pacientes e m\u00e9dicos em rela\u00e7\u00e3o &agrave; terapia de primeira linha a longo prazo. Os dados ser\u00e3o apresentados na ASCO e na EHA;<\/p>\n<\/li>\n<li>\numa an\u00e1lise de subgrupo do SEQUOIA, que inclui <b>uma das maiores e mais longas coortes de pacientes com idade igual ou superior a 80 anos j\u00e1 relatadas em um estudo de Fase 3 de LLC<\/b>, mostra que a idade n\u00e3o limita o benef\u00edcio. Os dados ser\u00e3o apresentados na EHA 2026;<\/p>\n<\/li>\n<li>\napresenta\u00e7\u00e3o oral, na EHA 2026<b>, de dados atualizados do degradador de BTK fundamental da BeOne, o BGB-16673, em pacientes com LLC recidivante\/refrat\u00e1ria<\/b>, demonstrando atividade promissora e duradoura, al\u00e9m de um perfil de seguran\u00e7a gerenci\u00e1vel. Tamb\u00e9m ser\u00e1 compartilhado um p\u00f4ster apresentando dados in\u00e9ditos do BGB-16673 em pacientes sem tratamento pr\u00e9vio com inibidores de BTK. O BGB-16673 \u00e9 o degradador de BTK mais avan\u00e7ado em ensaios cl\u00ednicos, tendo sido administrado a mais de 1.100 pacientes;<\/p>\n<\/li>\n<li>\nos dados da <b>combina\u00e7\u00e3o totalmente oral do inibidor fundamental de BCL2 da BeOne, venetoclax, mais o inibidor de tirosina quinase de Bruton (BTK) zanubrutinibe (ZS), em leucemia linfoc\u00edtica cr\u00f4nica (LLC)<\/b>, demonstraram respostas profundas, velocidade sem precedentes para doen\u00e7a residual m\u00ednima (DRM) indetect\u00e1vel, remiss\u00f5es duradouras e um perfil de seguran\u00e7a geralmente bem tolerado. Esses dados <b>refor\u00e7am o potencial de uma abordagem de pr\u00f3xima gera\u00e7\u00e3o, de dura\u00e7\u00e3o limitada<\/b>, projetada para oferecer resultados de longo prazo sem comprometer a durabilidade ou a seguran\u00e7a. Os dados ser\u00e3o apresentados em forma de p\u00f4ster na ASCO 2026 e em uma apresenta\u00e7\u00e3o oral na EHA 2026.<\/p>\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><strong>Acelerando um portf\u00f3lio de tumores s\u00f3lidos de alto potencial <\/strong><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA BeOne est\u00e1 destacando o forte impulso em seu amplo e diversificado portf\u00f3lio de tumores s\u00f3lidos na ASCO, com sete produtos exclusivos apresentados em tr\u00eas palestras e oito p\u00f4steres. Esses dados abrangem terapias em desenvolvimento e em comercializa\u00e7\u00e3o, incluindo resultados que demonstram o perfil diferenciado do inibidor de PD-1 TEVIMBRA<sup>\u00ae<\/sup> (tislelizumabe) em c\u00e2nceres de pulm\u00e3o e gastrointestinais, bem como sua combina\u00e7\u00e3o com o novo agente direcionado ao HER2, ZIIHERA<sup>\u00ae<\/sup> (zanidatamabe). A \u201csuperestrada\u201d de desenvolvimento da empresa est\u00e1 acelerando o progresso em todas as fases, gerando dados cl\u00ednicos convincentes que comprovam o potencial dessas terapias para transformar o tratamento em \u00e1reas com grande necessidade n\u00e3o atendida.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><strong>Mark Lanasa, M.D., Ph.D., diretor m\u00e9dico de Tumores S\u00f3lidos da BeOne Medicines, afirmou: <\/strong><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cNa ASCO 2026, estamos demonstrando a solidez da ci\u00eancia da BeOne, a amplitude de nosso pipeline e a velocidade com que estamos levando inova\u00e7\u00e3o aos pacientes. Com v\u00e1rios programas avan\u00e7ando simultaneamente para ensaios cl\u00ednicos decisivos, estamos construindo uma lideran\u00e7a duradoura no tratamento de c\u00e2nceres de mama, ginecol\u00f3gicos, de pulm\u00e3o e gastrointestinais \u2013 \u00e1reas onde ainda h\u00e1 uma necessidade substancial n\u00e3o atendida dos pacientes.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nAs principais apresenta\u00e7\u00f5es de dados em nossos programas de tumores s\u00f3lidos incluem:<\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li>\nprimeira divulga\u00e7\u00e3o dos efeitos antitumorais e do perfil de seguran\u00e7a\/tolerabilidade do <strong>inibidor de CDK4 altamente seletivo BGB-43395<\/strong>, com dados da Fase 1 do tratamento em c\u00e2ncer de mama HR-positivo\/HER2-negativo de primeira linha;<\/p>\n<\/li>\n<li><strong>apresenta\u00e7\u00e3o oral r\u00e1pida sobre o BG-C9074, um promissor conjugado anticorpo-f\u00e1rmaco (ADC) direcionado ao B7-H4, <\/strong>com dados da Fase 1 de escalonamento de dose e expans\u00e3o de seguran\u00e7a.\n<\/li>\n<li><strong>apresenta\u00e7\u00e3o oral r\u00e1pida sobre o BGB-B2033, um <\/strong><b>anticorpo biespec\u00edfico GPC3 x 4-1BB<\/b> potencialmente pioneiro na sua classe, com os primeiros dados cl\u00ednicos de um estudo de Fase 1 em pacientes com carcinoma hepatocelular que receberam tratamento pr\u00e9vio intensivo.\n<\/li>\n<li><b>Apresenta\u00e7\u00e3o oral r\u00e1pida<\/b> com uma an\u00e1lise de subgrupos de PD-L1 do estudo <b>HERIZON-GEA-01<\/b>, no qual o TEVIMBRA em combina\u00e7\u00e3o com o ZIIHERA e quimioterapia demonstrou uma melhora estatisticamente significativa na sobrevida global (SG) e na sobrevida livre de progress\u00e3o (SLP) em pacientes com adenocarcinoma gastroesof\u00e1gico HER2+, independentemente da express\u00e3o de PD-L1 (em parceria com a Jazz Pharmaceuticals).\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Webcast para investidores destacar\u00e1 dados do pipeline na ASCO<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA BeOne Medicines realizar\u00e1 um webcast para investidores no dia 1\u00ba de junho de 2026, \u00e0s 19h CDT\/20h EDT (21h, hor\u00e1rio de Bras\u00edlia), liderado por John V. Oyler, cofundador, presidente e CEO da empresa, juntamente com sua equipe de lideran\u00e7a e l\u00edderes de opini\u00e3o convidados. O webcast revisar\u00e1 os principais destaques cl\u00ednicos e corporativos da ASCO, oferecer\u00e1 atualiza\u00e7\u00f5es sobre o pipeline e as plataformas globais de P&amp;D da BeOne, e discutir\u00e1 as prioridades estrat\u00e9gicas e as capacidades de execu\u00e7\u00e3o que impulsionam o crescimento de longo prazo da empresa.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nOs detalhes de acesso ao webcast est\u00e3o dispon\u00edveis na se\u00e7\u00e3o de Investidores do site da BeOne em <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fir.beonemedicines.com&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=http%3A%2F%2Fir.beonemedicines.com&amp;index=2&amp;md5=e682e9e154fe39feea5e21a1ff1e4b56\" rel=\"follow\" shape=\"rect\" target=\"_blank\">http:\/\/ir.beonemedicines.com<\/a>, <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fhkexir.beonemedicines.com&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=https%3A%2F%2Fhkexir.beonemedicines.com&amp;index=3&amp;md5=0d725be8e1628d5503956f4a365506ad\" rel=\"follow\" shape=\"rect\" target=\"_blank\">https:\/\/hkexir.beonemedicines.com<\/a> e <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsseir.beonemedicines.com&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=https%3A%2F%2Fsseir.beonemedicines.com&amp;index=4&amp;md5=26f715be9b8964ee429157be238a85db\" rel=\"follow\" shape=\"rect\" target=\"_blank\">https:\/\/sseir.beonemedicines.com<\/a>. Um webcast arquivado estar\u00e1 dispon\u00edvel no site da empresa.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b><i>Lista completa das apresenta\u00e7\u00f5es da BeOne na ASCO:<\/i><\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b><i>Hematologia <\/i><\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BRUKINSA<sup>\u00ae<\/sup> (Zanubrutinibe) <\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTerapias subsequentes e tempo at\u00e9 o segundo evento de sobrevida livre de progress\u00e3o em pacientes com leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas, sem tratamento pr\u00e9vio, que receberam zanubrutinibe ou bendamustina-rituximabe no estudo SEQUOIA<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 544<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nConstantine S. Tam<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise do panorama atual dos inibidores p\u00f3s-covalentes da tirosina quinase de Bruton no linfoma de c\u00e9lulas do manto: observa\u00e7\u00f5es da pr\u00e1tica cl\u00ednica sobre padr\u00f5es de tratamento, interrup\u00e7\u00e3o do tratamento e utiliza\u00e7\u00e3o de recursos de sa\u00fade<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 556<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAlvaro Alencar<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados na pr\u00e1tica cl\u00ednica entre benefici\u00e1rios do Medicare tratados com inibidores da tirosina quinase de Bruton de primeira linha para leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 545<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDaniel A. Ermann<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpacto na pr\u00e1tica cl\u00ednica da fibrila\u00e7\u00e3o atrial nos resultados cardiovasculares e na utiliza\u00e7\u00e3o de recursos de sa\u00fade em pacientes com leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 540<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMichael Fradley<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados de sobreviv\u00eancia em condi\u00e7\u00f5es reais para a monoterapia com zanubrutinibe e acalabrutinibe em pacientes com leucemia linfoc\u00edtica cr\u00f4nica sem tratamento pr\u00e9vio nos Estados Unidos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 543<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRyan Jacobs<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUma compara\u00e7\u00e3o na pr\u00e1tica cl\u00ednica dos resultados de tratamento e sobrevida com a monoterapia com zanubrutinibe e acalabrutinibe em pacientes com linfoma de c\u00e9lulas do manto recidivante ou refrat\u00e1rio nos Estados Unidos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 560<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nYucai Wang<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIncid\u00eancia de mortes de origem card\u00edaca entre pacientes com 65 anos ou mais com neoplasias de c\u00e9lulas B tratados com ibrutinibe<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e19020<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRyan Jacobs<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFatores de risco para neoplasias malignas prim\u00e1rias secund\u00e1rias em pacientes com leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas: um estudo na pr\u00e1tica cl\u00ednica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e19022<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLili Zhou<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCaracteriza\u00e7\u00e3o da ades\u00e3o aos inibidores da BTK e dos sintomas relatados pelos pr\u00f3prios pacientes com LLC\/LLPC por meio de uma plataforma eletr\u00f4nica de resultados relatados pelos pacientes<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e19030<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMustafa Ascha<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUtiliza\u00e7\u00e3o de tratamentos na pr\u00e1tica cl\u00ednica, padr\u00f5es de sequenciamento e utiliza\u00e7\u00e3o de recursos de sa\u00fade na macroglobulinemia de Waldenstr\u00f6m<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e19056<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJorge Castillo<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sonrotoclax<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nO tratamento de primeira linha da LLC\/LLPC com a combina\u00e7\u00e3o totalmente oral de sonrotoclax e zanubrutinibe alcan\u00e7a taxas de doen\u00e7a residual m\u00ednima indetect\u00e1vel superiores a 90%, inclusive em pacientes com del(17p)\/ <i>TP53<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 541<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nConstantine S. Tam<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSonrotoclax + zanubrutinibe versus venetoclax + acalabrutinibe na leucemia linfoc\u00edtica cr\u00f4nica sem tratamento pr\u00e9vio: um estudo randomizado de fase 3 (CELESTIAL-TNCLL-2)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 596a<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Neoplasias hematol\u00f3gicas &#8211; Linfoma e leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMazyar Shadman<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfic\u00e1cia do sonrotoclax em compara\u00e7\u00e3o com o pirtobrutinibe no linfoma de c\u00e9lulas do manto recidivante\/refrat\u00e1rio ap\u00f3s tratamento com inibidores da tirosina quinase de Bruton: uma compara\u00e7\u00e3o indireta<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e19050<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAlvaro Alencar<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b><i>Tumores s\u00f3lidos<\/i><\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BGB-43395 (CDK4i)<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimeiros resultados do tratamento de primeira linha com o inibidor seletivo de CDK4 BGB-43395 em combina\u00e7\u00e3o com letrozol para o c\u00e2ncer de mama metast\u00e1tico HR+\/HER2\u2212: um estudo de expans\u00e3o de seguran\u00e7a de fase 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o de p\u00f4steres:<\/b> 180<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; C\u00e2ncer de mama &#8211; Metast\u00e1tico<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 13h30 \u00e0s 16h30 CDT (das 15h30 \u00e0s 18h30, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nShom Goel<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BG-C9074 (ADC direcionado ao B7-H4)<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEstudo de primeira linha em humanos do BG-C9074 (ADC direcionado ao B7-H4) em tumores s\u00f3lidos avan\u00e7ados: escalonamento de dose e avalia\u00e7\u00e3o da seguran\u00e7a<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Resumo oral r\u00e1pido:<\/b> 3013<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de resumos orais r\u00e1pidos &#8211; Terap\u00eautica do desenvolvimento &#8211; Agentes de alvo molecular e biologia tumoral<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 2 de junho de 2026, das 9h45 \u00e0s 11h15 CDT (das 11h45 \u00e0s 13h15, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBinghe Xu<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise da dosagem ajustada ao peso corporal ideal no estudo BG-C9074 (ADC direcionado a B7-H4) sob as perspectivas farmacocin\u00e9tica, de efic\u00e1cia e de seguran\u00e7a<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o de p\u00f4steres:<\/b> 166<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Terap\u00eautica em desenvolvimento &#8211; Agentes de alvo molecular e biologia tumoral<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 30 de maio de 2026, das 13h30 \u00e0s 16h30 CDT (das 15h30 \u00e0s 18h30, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHugh Giovinazzo<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BGB-B2033 (anticorpo biespec\u00edfico GPC3x4-1BB)<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUm estudo de fase 1 sobre a monoterapia com BGB-B2033 (anticorpo biespec\u00edfico GPC3 x 4-1BB) em pacientes com tumores s\u00f3lidos avan\u00e7ados ou metast\u00e1ticos selecionados: primeira divulga\u00e7\u00e3o dos dados cl\u00ednicos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Resumo oral r\u00e1pido:<\/b> 3016<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de resumos orais r\u00e1pidos &#8211; Terap\u00eautica do desenvolvimento &#8211; Agentes de alvo molecular e biologia tumoral<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 2 de junho de 2026, das 9h45 \u00e0s 11h15 CDT (das 11h45 \u00e0s 13h15, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHong Jae Chon<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>TEVIMBRA<sup>\u00ae<\/sup> (tislelizumabe) e ZIIHERA<sup>\u00ae<\/sup> (zanidatamabe) <\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nZanidatamabe + quimioterapia \u00b1 tislelizumabe no tratamento de primeira linha do adenocarcinoma gastroesof\u00e1gico HER2-positivo, localmente avan\u00e7ado ou metast\u00e1tico: an\u00e1lise de subgrupos de PD-L1 do estudo HERIZON-GEA-01<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Resumo oral r\u00e1pido:<\/b> 4010<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Resumo oral r\u00e1pido<br \/>\n<br \/>Sess\u00e3o \u2013 Gastrointestinal<br \/>\n<br \/>C\u00e2ncer gastroesof\u00e1gico,<br \/>\n<br \/>pancre\u00e1tico e hepatobiliar<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 1\u00ba de junho de 2026, das 13h15 \u00e0s 14h45 CDT (das 15h15 \u00e0s 16h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSunYoung Rha<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCaracteriza\u00e7\u00e3o e manejo dos eventos adversos gastrointestinais associados ao zanidatamabe + quimioterapia \u00b1 tislelizumabe no tratamento de primeira linha do adenocarcinoma gastroesof\u00e1gico HER2-positivo, localmente avan\u00e7ado ou metast\u00e1tico: An\u00e1lise do estudo HERIZON-GEA-01<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 25<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres \u2013<\/p>\n<p class=\"bwcellpmargin\">\nC\u00e2ncer gastrointestinal-<\/p>\n<p class=\"bwcellpmargin\">\ngastroesof\u00e1gico, pancre\u00e1tico,<\/p>\n<p class=\"bwcellpmargin\">\ne hepatobiliar<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 30 de maio de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s<br \/>\n<br \/>14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nElena Elimova<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>TEVIMBRA<sup>\u00ae<\/sup> (tislelizumabe) <\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRATIONALE-315: An\u00e1lise post hoc da sobrevida livre de eventos em subgrupos cirurgicamente relevantes tratados com tislelizumabe no per\u00edodo perioperat\u00f3rio e quimioterapia neoadjuvante versus quimioterapia neoadjuvante<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 533<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; C\u00e2ncer de pulm\u00e3o &#8211; C\u00e2ncer de pulm\u00e3o de c\u00e9lulas n\u00e3o pequenas (local-regional)\/de c\u00e9lulas pequenas\/outros tipos de c\u00e2ncer tor\u00e1cico<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 31 de maio de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGustavo Schvartsman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCompara\u00e7\u00e3o da sobrevida ajustada pela qualidade entre tislelizumabe + quimioterapia (QT) e placebo + QT como tratamento de primeira linha em pacientes com adenocarcinoma g\u00e1strico ou da jun\u00e7\u00e3o gastroesof\u00e1gica com met\u00e1stase peritoneal: acompanhamento de longo prazo do estudo RATIONALE-305<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Apresenta\u00e7\u00e3o de p\u00f4ster:<\/b> 17<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; C\u00e2ncer gastrointestinal &#8211; Gastroesof\u00e1gico, pancre\u00e1tico e hepatobiliar<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 30 de maio de 2026, das 9h \u00e0s 12h CDT (das 11h \u00e0s 14h, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRutika Mehta<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUma nova abordagem bayesiana para avaliar as associa\u00e7\u00f5es entre o \u00edndice de desempenho ECOG e os resultados relatados pelos pacientes em pacientes com adenocarcinoma g\u00e1strico ou da jun\u00e7\u00e3o gastroesof\u00e1gica: an\u00e1lise post hoc do estudo RATIONALE-305<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> e16044<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMarcia Cruz-Correa<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Ociperlimab<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise explorat\u00f3ria de biomarcadores do tratamento com ociperlimab mais tislelizumabe em pacientes com c\u00e2ncer de pulm\u00e3o de c\u00e9lulas n\u00e3o pequenas PD-L1-positivo no estudo AdvanTIG-105<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o de p\u00f4steres:<\/b> 361<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Terap\u00eautica em desenvolvimento &#8211; Imunoterapia<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 30 de maio de 2026, das 13h30 \u00e0s 16h30 (hor\u00e1rio central dos EUA)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJun Zhang<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BGB-A3055 (anti-CCR8)<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUm estudo de fase 1 do BGB-A3055 (anti-CCR8), com ou sem tislelizumabe (anti-PD-1), em pacientes com tumores s\u00f3lidos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o de p\u00f4steres:<\/b> 313<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>T\u00edtulo da sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres &#8211; Terap\u00eautica em desenvolvimento &#8211; Imunoterapia<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 30 de maio de 2026, das 13h30 \u00e0s 16h30 CDT (das 15h30 \u00e0s 18h30, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJudith Raimbourg<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b><i>Lista completa das apresenta\u00e7\u00f5es da BeOne na EHA:<\/i><\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Zanubrutinibe<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAcompanhamento de longo prazo da seguran\u00e7a e da efic\u00e1cia do zanubrutinibe em pacientes idosos (\u2265 80 anos) com LLC\/LLPC que nunca receberam tratamento, incluindo aqueles com del(17p): an\u00e1lise de subgrupos do estudo SEQUOIA.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1703<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAlessandra Tedeschi<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTerapias subsequentes e tempo at\u00e9 o segundo evento de sobrevida livre de progress\u00e3o na leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas previamente tratados com zanubrutinibe ou bendamustina-rituximabe<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF601<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMazyar Shadman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nZanubrutinibe versus ibrutinibe na leucemia linfoc\u00edtica cr\u00f4nica (LLC) sem tratamento pr\u00e9vio: implica\u00e7\u00f5es para a interpreta\u00e7\u00e3o dos resultados de tratamentos de dura\u00e7\u00e3o fixa do estudo CLL17<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1718<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTalha Munir<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAssocia\u00e7\u00f5es entre o \u00edndice de desempenho ECOG e os resultados relatados por pacientes com leucemia linfoc\u00edtica cr\u00f4nica ou linfoma linfoc\u00edtico pequeno em recidiva ou refrat\u00e1rio: an\u00e1lise p\u00f3s-hoc do estudo ALPINE<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2492<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNicole Lamanna<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise longitudinal de pacientes com LLC\/LLPC que apresentavam pontua\u00e7\u00f5es comprometidas na qualidade de vida relacionada &agrave; sa\u00fade no in\u00edcio do estudo e que foram tratados com zanubrutinibe versus ibrutinibe: uma an\u00e1lise p\u00f3s-hoc do estudo ALPINE.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF1398<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoic Ysebaert<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPadr\u00f5es de tratamento com zanubrutinibe no mundo real em pacientes com LLC\/LLPC em oncologia comunit\u00e1ria nos EUA com terapia pr\u00e9via com acalabrutinibe.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF618<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJing-Zhou Hou<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPadr\u00f5es de utiliza\u00e7\u00e3o e sequenciamento do tratamento em diferentes linhas de terapia na macroglobulinemia de Waldenstr\u00f6m: Evid\u00eancias do mundo real nos Estados Unidos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2516<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrashant Kapoor<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise comparativa no mundo real da descontinua\u00e7\u00e3o do tratamento com inibidores covalentes da tirosina quinase de Bruton em leucemia linfoc\u00edtica cr\u00f4nica de primeira linha.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1710<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNakhle Saba<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados do tratamento e da sobrevida no mundo real para monoterapia com zanubrutinibe e acalabrutinibe em pacientes com leucemia linfoc\u00edtica cr\u00f4nica sem tratamento pr\u00e9vio nos Estados Unidos.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF608<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRyan Jacobs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCompara\u00e7\u00e3o, no mundo real, dos resultados de tratamento e sobrevida com monoterapia de zanubrutinibe e acalabrutinibe em pacientes com linfoma de c\u00e9lulas do manto recidivado ou refrat\u00e1rio nos Estados Unidos.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2040<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nYucai Wang<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados cl\u00ednicos em pacientes com linfoma de c\u00e9lulas do manto recidivante\/refrat\u00e1rio tratados com zanubrutinibe ou acalabrutinibe na pr\u00e1tica cl\u00ednica nos Estados Unidos<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF958<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJavier Munoz<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpacto na pr\u00e1tica cl\u00ednica da fibrila\u00e7\u00e3o atrial nos resultados cardiovasculares e na utiliza\u00e7\u00e3o de recursos de sa\u00fade em pacientes com leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2515<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRhys Williams<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCarga do tratamento em pacientes com 75 anos ou mais com leucemia linfoc\u00edtica cr\u00f4nica e linfoma linfoc\u00edtico pequeno<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF605<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDaniel Ermann<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfic\u00e1cia e seguran\u00e7a do zanubrutinibe na macroglobulinemia de Waldenstr\u00f6m na pr\u00e1tica cl\u00ednica: Resultados do estudo belga WIZARD<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB3600<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWillem Daneels<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExperi\u00eancia cl\u00ednica com zanubrutinibe na leucemia linfoc\u00edtica cr\u00f4nica \u2014 perfil dos pacientes, padr\u00f5es de tratamento e seguran\u00e7a: an\u00e1lise preliminar do estudo franc\u00eas ROZALY<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2898<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFlorian Bouclet<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBRUMIZE: Uso do zanubrutinibe na pr\u00e1tica cl\u00ednica e seguran\u00e7a preliminar no linfoma da zona marginal recidivante\/refrat\u00e1rio na Europa<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB3632<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nC\u00f4me Bommier<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCompara\u00e7\u00e3o indireta da efic\u00e1cia do zanubrutinibe versus acalabrutinibe e ibrutinibe em pacientes com leucemia linfoc\u00edtica cr\u00f4nica sem tratamento pr\u00e9vio<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2895<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMazyar Shadman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados relatados pelos pacientes e progress\u00e3o da doen\u00e7a na leucemia linfoc\u00edtica cr\u00f4nica e no linfoma linfoc\u00edtico pequeno: uma revis\u00e3o sistem\u00e1tica da literatura e an\u00e1lise das lacunas<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2909<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoic Ysebaert<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCompreender as perspectivas e prefer\u00eancias dos pacientes em rela\u00e7\u00e3o ao tratamento de primeira linha da leucemia linfoc\u00edtica cr\u00f4nica na Europa<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2934<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLydia Scarf\u00f2<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nN\u00famero de mortes evitadas com o uso de zanubrutinibe em compara\u00e7\u00e3o com o ibrutinibe no tratamento da leucemia linfoc\u00edtica cr\u00f4nica na Europa<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2944<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTalha Munir<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUtiliza\u00e7\u00e3o da imunoglobulina intravenosa na pr\u00e1tica cl\u00ednica em pacientes com leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas tratados com venetoclax mais obinutuzumabe versus zanubrutinibe<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2915<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNicole Lamanna<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResultados na pr\u00e1tica cl\u00ednica entre benefici\u00e1rios do Medicare tratados com inibidores da tirosina quinase de Bruton de primeira linha para leucemia linfoc\u00edtica cr\u00f4nica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2901<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDaniel A. Ermann<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise das prefer\u00eancias dos pacientes e hematologistas quanto \u00e0s caracter\u00edsticas do tratamento da leucemia linfoc\u00edtica cr\u00f4nica: um estudo qualitativo na Europa<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB4474<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLydia Scarf\u00f2<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sonrotoclax<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nO tratamento de primeira linha da LLC\/LLPC com a combina\u00e7\u00e3o totalmente oral de sonrotoclax e zanubrutinibe atinge taxas de doen\u00e7a residual m\u00ednima indetect\u00e1vel superiores a 90%, inclusive em pacientes com del(17p)\/<i>TP53<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> S145<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> s424 \u2014 Progn\u00f3stico e terapia de primeira linha na LLC (leucemia linfoc\u00edtica cr\u00f4nica)<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026,<\/p>\n<p class=\"bwcellpmargin\">\ndas 17h15 \u00e0s 18h30 CEST (das 12h15 \u00e0s 13h30, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nChan Y. Cheah<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAtualiza\u00e7\u00e3o sobre a seguran\u00e7a e efic\u00e1cia do sonrotoclax totalmente oral + zanubrutinibe em leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de pequenas c\u00e9lulas recidivado\/refrat\u00e1rio, incluindo pacientes com del(17p)\/<i>TP53<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1697<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStephen S. Opat<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTratamento combinado com o novo inibidor de BCL2, soncotoclax (BGB-11417) e zanubrutinibe em pacientes com linfoma de c\u00e9lulas do manto recidivado\/refrat\u00e1rio: resultados de um estudo de fase 1\/1b.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF933<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJacob D. Soumerai<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEstudo de fase 1\/2 da monoterapia com sonrotoclax (BGB-11417) em linfoma de c\u00e9lulas do manto recidivado\/refrat\u00e1rio pr\u00e9-tratado com inibidor da tirosina quinase de Bruton: uma an\u00e1lise da subpopula\u00e7\u00e3o chinesa.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PF961<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 1<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 12 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nYuqin Song<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSonrotoclax (BGB-11417) + zanubrutinibe versus venetoclax + acalabrutinibe em leucemia linfoc\u00edtica cr\u00f4nica n\u00e3o tratada previamente: um estudo randomizado de fase 3 (CELESTIAL-TNCLL-2)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2966<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMazyar Shadman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfic\u00e1cia do sonrotoclax versus pirtobrutinibe no tratamento de linfoma de c\u00e9lulas do manto recidivado\/refrat\u00e1rio ap\u00f3s inibidor da tirosina quinase de Bruton: uma compara\u00e7\u00e3o indireta.<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB3626<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nToby A. Eyre<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAn\u00e1lise do panorama atual dos inibidores p\u00f3s-covalentes da tirosina quinase de Bruton no linfoma de c\u00e9lulas do manto: observa\u00e7\u00f5es da pr\u00e1tica cl\u00ednica sobre padr\u00f5es de tratamento, interrup\u00e7\u00e3o do tratamento e utiliza\u00e7\u00e3o de recursos de sa\u00fade<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB3617<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nToby A. Eyre<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRisco de s\u00edndrome de lise tumoral em pacientes com leucemia linfoc\u00edtica cr\u00f4nica ou linfoma de c\u00e9lulas do manto tratados com venetoclax: um estudo na pr\u00e1tica cl\u00ednica<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2896<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAlessandra Ferrajoli<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>BGB-16673<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBGB-16673, um inibidor da tirosina quinase de Bruton, em pacientes com leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas recidivante\/refrat\u00e1rio: uma atualiza\u00e7\u00e3o do estudo de fase 1 CaDAnCe-101<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> S152<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> s449 \u2013 Novas terapias para a LLC recidivante\/refrat\u00e1ria<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 14 de junho de 2026,<\/p>\n<p class=\"bwcellpmargin\">\ndas 11h \u00e0s 12h15 CEST (das 6h \u00e0s 7h15, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStephan Stilgenbauer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nO degradador da tirosina quinase de Bruton (BTK) BGB-16673 em pacientes com LLC\/LLPC e outras neoplasias de c\u00e9lulas B que nunca receberam inibidores da BTK: Resultados do estudo de fase 1 CaDAnCe-101<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1693<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 (CEST)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIrina Mocanu<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBGB-16673, um degradador da tirosina quinase de Bruton, em pacientes com macroglobulinemia de Waldenstr\u00f6m recidivante\/refrat\u00e1ria: uma atualiza\u00e7\u00e3o do estudo de fase 1 CaDAnCe-101<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2033<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 (CEST)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJudith Trotman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nO BGB-16673, um degradador da tirosina quinase de Bruton, apresenta baixo risco de intera\u00e7\u00e3o medicamentosa (IM) mediada pelo CYP3A: resultados do estudo de Fase 1 sobre absor\u00e7\u00e3o, distribui\u00e7\u00e3o, metabolismo e excre\u00e7\u00e3o, bem como sobre intera\u00e7\u00f5es medicamentosas<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS1711<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 (CEST)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJudith Trotman<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBGB-16673 versus idelalisibe + rituximabe (R), bendamustina + R ou venetoclax + R como retratamento em pacientes com leucemia linfoc\u00edtica cr\u00f4nica\/linfoma linfoc\u00edtico de c\u00e9lulas pequenas: o estudo de fase 3 CaDAnCe-302<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero do resumo:<\/b> PB2925<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPaolo Ghia<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Tislelizumabe<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>T\u00edtulo do resumo<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Detalhes da apresenta\u00e7\u00e3o<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Autor principal<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAvalia\u00e7\u00e3o de par\u00e2metros de PET-CT e farmacocin\u00e9tica em adultos em tratamento com tislelizumabe para linfoma de Hodgkin cl\u00e1ssico recidivante\/refrat\u00e1rio: An\u00e1lises complementares do estudo LYSA de fase 2 TIRHOL (BGB-A317-210)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b>N\u00famero da publica\u00e7\u00e3o:<\/b> PS2028<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Sess\u00e3o:<\/b> Sess\u00e3o de p\u00f4steres 2<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\"><b>Data e hora da sess\u00e3o:<\/b> 13 de junho de 2026, das 18h45 \u00e0s 19h45 CEST (das 13h45 \u00e0s 14h45, hor\u00e1rio de Bras\u00edlia)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth20\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHerv\u00e9 Ghesqui\u00e8res<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre o BRUKINSA<sup>\u00ae<\/sup> (zanubrutinibe) <\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO BRUKINSA \u00e9 um inibidor de mol\u00e9cula pequena da tirosina quinase de Bruton (BTK), administrado por via oral, projetado para fornecer uma inibi\u00e7\u00e3o completa e sustentada da prote\u00edna BTK, otimizando biodisponibilidade, meia-vida e seletividade. Com uma farmacocin\u00e9tica diferenciada em compara\u00e7\u00e3o com outros inibidores de BTK aprovados, o BRUKINSA demonstrou inibir a prolifera\u00e7\u00e3o de c\u00e9lulas B malignas em diversos tecidos associados &agrave; doen\u00e7a.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nCom a indica\u00e7\u00e3o mais ampla do mundo, o BRUKINSA \u00e9 o inibidor de BTK de refer\u00eancia. \u00c9 tamb\u00e9m o \u00fanico inibidor de BTK com flexibilidade de administra\u00e7\u00e3o, uma ou duas vezes ao dia, e o \u00fanico a demonstrar superioridade em rela\u00e7\u00e3o a outro inibidor de BTK em um estudo de Fase 3.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO programa global de desenvolvimento cl\u00ednico do BRUKINSA inclui mais de 8.000 pacientes recrutados em mais de 30 pa\u00edses e regi\u00f5es, distribu\u00eddos em mais de 45 ensaios cl\u00ednicos. O BRUKINSA est\u00e1 aprovado em 80 mercados para pelo menos uma indica\u00e7\u00e3o, e mais de 290.000 pacientes j\u00e1 foram tratados em todas as partes do mundo.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre o BEQALZI<sup>\u2122<\/sup> (sonrotoclax) <\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nBEQALZI<sup>\u2122<\/sup> (sonrotoclax) \u00e9 um inibidor fundamental de linfoma de c\u00e9lulas B2 (BCL2) de pr\u00f3xima gera\u00e7\u00e3o, com um perfil farmacocin\u00e9tico e farmacodin\u00e2mico \u00fanico, e potencialmente o melhor da classe. Estudos pr\u00e9-cl\u00ednicos e cl\u00ednicos realizados no in\u00edcio do desenvolvimento do medicamento demonstraram que o sonrotoclax \u00e9 um inibidor de BCL2 altamente potente e espec\u00edfico, com meia-vida curta e sem ac\u00famulo do f\u00e1rmaco. O BEQALZI demonstrou atividade cl\u00ednica promissora em diversos tipos de malignidades de c\u00e9lulas B, incluindo leucemia linfoc\u00edtica cr\u00f4nica (LLC), e est\u00e1 sendo desenvolvido para uso como monoterapia e em combina\u00e7\u00e3o com outras terapias, incluindo o uso de zanubrutinibe. At\u00e9 o momento, mais de 2.200 pacientes foram inscritos no amplo programa global de desenvolvimento do sonrotoclax.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre o BGB-16673<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO BGB-16673 \u00e9 um degradador de tirosina quinase de Bruton (BTK), sendo potencialmente o primeiro e melhor da sua classe para o tratamento de neoplasias de c\u00e9lulas B. Com mais de 1.100 pacientes tratados at\u00e9 o momento em um extenso programa global de desenvolvimento cl\u00ednico, ele \u00e9 o degradador de BTK mais avan\u00e7ado em ensaios cl\u00ednicos. Esse programa inclui tr\u00eas estudos randomizados de fase 3 em leucemia linfoc\u00edtica cr\u00f4nica (LLC) recidivante\/refrat\u00e1ria, incluindo o estudo comparativo direto de fase 3 versus pirtobrutinibe, que iniciou o recrutamento no quarto trimestre de 2025. Origin\u00e1rio da plataforma de compostos quim\u00e9ricos de ativa\u00e7\u00e3o da degrada\u00e7\u00e3o (CDAC) da BeOne, o BGB-16673 foi projetado para promover a degrada\u00e7\u00e3o tanto das formas selvagens quanto mutantes da BTK, incluindo aquelas que comumente resultam em resist\u00eancia a inibidores de BTK em pacientes com doen\u00e7a progressiva.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Administra\u00e7\u00e3o de Alimentos e Medicamentos dos EUA (FDA) concedeu a designa\u00e7\u00e3o de via r\u00e1pida ao BGB-16673 para tratamento de pacientes adultos com leucemia linfoc\u00edtica cr\u00f4nica ou linfoma linfoc\u00edtico de pequenas c\u00e9lulas (LLC\/LLPC) reincidente ou refrat\u00e1rio (RR), e pacientes adultos com linfoma de c\u00e9lulas do manto (LCM) RR. Al\u00e9m disto, a Ag\u00eancia Europeia de Medicamentos (EMA) concedeu ao BGB-16673 a designa\u00e7\u00e3o de medicamento priorit\u00e1rio (PRIME) para tratamento de pacientes com macroglobulinemia de Waldenstr\u00f6m (MW) previamente tratados com um inibidor de BTK.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre o ZIIHERA (zanidatamabe)<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO ZIIHERA (zanidatamabe) \u00e9 um anticorpo biespec\u00edfico direcionado ao receptor 2 do fator de crescimento epid\u00e9rmico humano (HER2), que se liga a dois s\u00edtios extracelulares no HER2. A liga\u00e7\u00e3o do ZIIHERA ao HER2 resulta na internaliza\u00e7\u00e3o do receptor, reduzindo sua express\u00e3o na superf\u00edcie das c\u00e9lulas tumorais. O ZILHERA induz a citotoxicidade dependente do complemento (CDC), a citotoxicidade celular dependente de anticorpos (ADCC) e a fagocitose celular dependente de anticorpos (ADCP). Esses mecanismos resultam na inibi\u00e7\u00e3o do crescimento tumoral e na morte celular, tanto in vitro quanto in vivo.<sup>1<\/sup><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO zanidatamabe est\u00e1 sendo desenvolvido em m\u00faltiplos ensaios cl\u00ednicos como uma op\u00e7\u00e3o de tratamento direcionado para pacientes com tumores s\u00f3lidos que expressam HER2. O zanidatamabe foi aprovado na China para o tratamento de pacientes com c\u00e2ncer do trato biliar (CTB) irressec\u00e1vel, localmente avan\u00e7ado ou metast\u00e1tico com alta express\u00e3o de HER2 (IHC 3+) e que receberam terapia sist\u00eamica pr\u00e9via. O ZIIHERA tamb\u00e9m recebeu aprova\u00e7\u00e3o acelerada nos EUA e autoriza\u00e7\u00e3o condicional de comercializa\u00e7\u00e3o na Uni\u00e3o Europeia para pacientes eleg\u00edveis com CTB. O zanidatamabe est\u00e1 sendo desenvolvido pela Jazz e pela BeOne sob contratos de licenciamento com a Zymeworks, que desenvolveu a mol\u00e9cula inicialmente. A BeOne licenciou o zanidatamabe da Zymeworks na \u00c1sia (exceto \u00cdndia e Jap\u00e3o), Austr\u00e1lia e Nova Zel\u00e2ndia. A Jazz Pharmaceuticals det\u00e9m os direitos em todas as outras regi\u00f5es.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nZIIHERA \u00e9 uma marca registrada da Zymeworks BC Inc.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre o TEVIMBRA (tislelizumabe)<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO TEVIMBRA \u00e9 um anticorpo monoclonal de imunoglobulina G4 humanizada (IgG4) anti-prote\u00edna de morte celular programada 1 (PD-1) de design exclusivo com alta afinidade e especificidade de liga\u00e7\u00e3o contra PD-1. Ele foi projetado para minimizar a liga\u00e7\u00e3o aos receptores Fc-gama (Fc\u03b3) nos macr\u00f3fagos, ajudando as c\u00e9lulas imunol\u00f3gicas do corpo a detectarem e combaterem tumores.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO TEVIMBRA \u00e9 o principal produto do portf\u00f3lio de tumores s\u00f3lidos da BeOne, tendo demonstrado potencial em diversos tipos de tumores e contextos cl\u00ednicos. Seu programa global de desenvolvimento cl\u00ednico inclui quase 15 mil pacientes inscritos at\u00e9 o momento, em mais de 30 pa\u00edses e regi\u00f5es, em 71 ensaios cl\u00ednicos, incluindo 21 estudos de registro. O TEVIMBRA est\u00e1 aprovado em mais de 50 pa\u00edses e j\u00e1 foi utilizado para tratar mais de 2 milh\u00f5es de pacientes globalmente.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Informa\u00e7\u00f5es importantes de seguran\u00e7a sobre o BRUKINSA\u00ae (zanubrutinibe)<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nRea\u00e7\u00f5es adversas graves, incluindo eventos fatais, ocorreram com o BRUKINSA, entre elas hemorragias, infec\u00e7\u00f5es, citopenias, neoplasias malignas prim\u00e1rias secund\u00e1rias, arritmias card\u00edacas e hepatotoxicidade (incluindo les\u00e3o hep\u00e1tica induzida por medicamentos).<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nNa popula\u00e7\u00e3o de seguran\u00e7a combinada (N=1729), as rea\u00e7\u00f5es adversas mais comuns (\u226530%), incluindo altera\u00e7\u00f5es laboratoriais, em pacientes que receberam BRUKINSA foram diminui\u00e7\u00e3o da contagem de neutr\u00f3filos (51%), diminui\u00e7\u00e3o da contagem de plaquetas (41%), infec\u00e7\u00e3o do trato respirat\u00f3rio superior (38%), hemorragia (32%) e dor musculoesquel\u00e9tica (31%).<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nConsulte as Informa\u00e7\u00f5es de <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2FPDF%2FBRUKINSAUSPI.pdf&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Prescri%26ccedil%3B%26atilde%3Bo+Completas+dos+EUA&amp;index=5&amp;md5=edb242c8a141a63f5d9907c2cbe328a1\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Prescri\u00e7\u00e3o Completas dos EUA<\/a>, incluindo as <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2FPDF%2FBRUKINSAUSPPI.pdf&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Informa%26ccedil%3B%26otilde%3Bes+para+o+Paciente+nos+EUA&amp;index=6&amp;md5=4ad501334be5026897f3ca69fcdc6182\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Informa\u00e7\u00f5es para o Paciente nos EUA<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Informa\u00e7\u00f5es importantes de seguran\u00e7a sobre o BEQALZI<sup>\u2122<\/sup> (sonrotoclax) <\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nRea\u00e7\u00f5es adversas graves e, em alguns casos, fatais foram observadas com o uso do Beqezil, incluindo s\u00edndrome de lise tumoral (SLT), infec\u00e7\u00f5es graves, neutropenia e toxicidade embriofetal. O uso de inibidores potentes do CYP3A \u00e9 contraindicado no in\u00edcio do tratamento e durante a fase de aumento gradual da dose, devido ao potencial aumento do risco de SLT.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nEntre os 115 pacientes da popula\u00e7\u00e3o de seguran\u00e7a, 7% desenvolveram s\u00edndrome de lise tumoral ao seguirem o aumento gradual da dose recomendado. Infec\u00e7\u00f5es graves ocorreram em 14% dos pacientes e infec\u00e7\u00f5es de grau 3 ou 4, em 17% (fatais em 2,6%), sendo a pneumonia (10%) a mais comum entre as infec\u00e7\u00f5es de grau 3 ou superior. Diminui\u00e7\u00f5es de grau 3 ou 4 nos neutr\u00f3filos ocorreram em 18% dos pacientes (grau 4: 6%), e neutropenia febril, em 1,7%. As rea\u00e7\u00f5es adversas mais comuns (ocorrendo em \u226515% dos pacientes) foram pneumonia (16%) e fadiga (16%). As anormalidades laboratoriais de grau 3-4 mais comuns (\u2265 15%) foram diminui\u00e7\u00e3o de linf\u00f3citos (29%) e de neutr\u00f3filos (18%).<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nConsulte as <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpicentral.beonemedicines.com%2F%3Fcountry%3Dus%26product%3Dbeqalzi%26doc_type%3Dfpi&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Informa%26ccedil%3B%26otilde%3Bes+de+Prescri%26ccedil%3B%26atilde%3Bo&amp;index=7&amp;md5=dda26ee102ff54d34390ca5f5ca31744\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Informa\u00e7\u00f5es de Prescri\u00e7\u00e3o<\/a> completas.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Selecione Informa\u00e7\u00f5es Importantes de Seguran\u00e7a sobre o TEVIMBRA<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nOcorreram rea\u00e7\u00f5es adversas graves e \u00e0s vezes fatais com o tratamento com TEVIMBRA. As advert\u00eancias e precau\u00e7\u00f5es incluem rea\u00e7\u00f5es adversas imunomediadas graves e fatais, incluindo pneumonite, colite, hepatite, endocrinopatias, rea\u00e7\u00f5es adversas dermatol\u00f3gicas, nefrite com disfun\u00e7\u00e3o renal e rejei\u00e7\u00e3o de transplante de \u00f3rg\u00e3os s\u00f3lidos. Outras advert\u00eancias e precau\u00e7\u00f5es incluem rea\u00e7\u00f5es relacionadas &agrave; infus\u00e3o, complica\u00e7\u00f5es do TCTH alog\u00eanico e toxicidade embriofetal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nConsulte as <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2FPDF%2FTEVIMBRAUSPI.pdf&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Informa%26ccedil%3B%26otilde%3Bes+Completas+sobre+Prescri%26ccedil%3B%26atilde%3Bo+nos+EUA&amp;index=8&amp;md5=4119c6db9a6078edba60f3866d2e2569\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Informa\u00e7\u00f5es Completas sobre Prescri\u00e7\u00e3o nos EUA<\/a>, incluindo o <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2FPDF%2FTEVIMBRAUSMG.pdf&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Guia+do+Medicamento+dos+EUA&amp;index=9&amp;md5=eab52f2a44a0912d0a59c6a87722a5f5\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Guia do Medicamento dos EUA<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>As informa\u00e7\u00f5es contidas neste comunicado &agrave; imprensa destinam-se a um p\u00fablico global. As indica\u00e7\u00f5es dos produtos variam de acordo com a regi\u00e3o.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a BeOne<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA BeOne Medicines \u00e9 uma empresa global de oncologia que descobre e desenvolve tratamentos inovadores para pacientes com c\u00e2ncer em todo o mundo. Com um portf\u00f3lio que abrange hematologia e tumores s\u00f3lidos, a BeOne acelera o desenvolvimento de sua diversificada linha de novas terapias por meio de suas capacidades internas e colabora\u00e7\u00f5es. A empresa conta com uma equipe global em expans\u00e3o, presente em seis continentes, impulsionada pela excel\u00eancia cient\u00edfica e pela excepcional agilidade para alcan\u00e7ar mais pacientes do que nunca. Para saber mais sobre a BeOne, acesse <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.beonemedicines.com&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=www.beonemedicines.com&amp;index=10&amp;md5=371aebed44c775eb82cdfb4f07bc802f\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.beonemedicines.com<\/a> e nos siga no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbeonemedicines%2F&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=LinkedIn&amp;index=11&amp;md5=af18c88714f76c4e84d8ca2d1da1b09d\" rel=\"follow\" shape=\"rect\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FBeOneMedicines&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=X&amp;index=12&amp;md5=a3c23d232250f2eb82711fd29762d9dc\" rel=\"follow\" shape=\"rect\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FBeOneMeds&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Facebook&amp;index=13&amp;md5=e9062f7d3e3bac9628d96e4d30536aaf\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Facebook<\/a> e <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fbeonemedicines%2F&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Instagram&amp;index=14&amp;md5=cb95327bf3fb403059f8d7f52f638416\" rel=\"follow\" shape=\"rect\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Declara\u00e7\u00f5es prospectivas<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nEste comunicado &agrave; imprensa cont\u00e9m declara\u00e7\u00f5es prospectivas, conforme definido na Lei de Reforma de Lit\u00edgios de Valores Mobili\u00e1rios Privados de 1995 (Private Securities Litigation Reform Act of 1995) e em outras leis federais de valores mobili\u00e1rios, incluindo afirma\u00e7\u00f5es sobre a capacidade da BeOne de avan\u00e7ar com futuros tratamentos e de liderar na \u00e1rea de hematologia, de construir uma lideran\u00e7a duradoura no tratamento de tumores s\u00f3lidos, de desenvolver programas cl\u00ednicos e de estabelecer planos, compromissos, aspira\u00e7\u00f5es e metas, conforme o t\u00edtulo \u201cSobre a BeOne\u201d. Os resultados reais podem diferir materialmente daqueles indicados nas declara\u00e7\u00f5es prospectivas em decorr\u00eancia de v\u00e1rios fatores importantes, incluindo a capacidade da BeOne de demonstrar a efic\u00e1cia e a seguran\u00e7a de seus medicamentos em desenvolvimento; os resultados cl\u00ednicos desses medicamentos, que podem n\u00e3o justificar o desenvolvimento adicional ou a aprova\u00e7\u00e3o de comercializa\u00e7\u00e3o; as a\u00e7\u00f5es de ag\u00eancias reguladoras, que podem afetar o in\u00edcio, o cronograma e o progresso dos ensaios cl\u00ednicos, bem como a aprova\u00e7\u00e3o de comercializa\u00e7\u00e3o; a capacidade da BeOne de alcan\u00e7ar sucesso comercial com seus medicamentos, caso sejam aprovados; e a capacidade da BeOne de obter e manter a prote\u00e7\u00e3o da propriedade intelectual de seus medicamentos e tecnologia; a depend\u00eancia da BeOne de terceiros para conduzir o desenvolvimento, a fabrica\u00e7\u00e3o, a comercializa\u00e7\u00e3o e outros servi\u00e7os relacionados a medicamentos; a experi\u00eancia limitada da BeOne na obten\u00e7\u00e3o de aprova\u00e7\u00f5es regulat\u00f3rias e na comercializa\u00e7\u00e3o de produtos farmac\u00eauticos, bem como sua capacidade de obter financiamento adicional para opera\u00e7\u00f5es, concluir o desenvolvimento de seus candidatos a medicamentos e alcan\u00e7ar e manter a lucratividade; e os riscos discutidos mais detalhadamente na se\u00e7\u00e3o &#8220;Fatores de Risco&#8221; do relat\u00f3rio trimestral mais recente da empresa no Formul\u00e1rio 10-Q, al\u00e9m das discuss\u00f5es sobre riscos potenciais, incertezas e outros fatores importantes em seus registros subsequentes junto &agrave; Comiss\u00e3o de Valores Mobili\u00e1rios dos EUA (U.S. Securities and Exchange Commission \u2013 SEC). Todas as informa\u00e7\u00f5es contidas neste comunicado &agrave; imprensa s\u00e3o v\u00e1lidas na data de sua publica\u00e7\u00e3o, e a BeOne n\u00e3o se compromete a atualiz\u00e1-las, a menos que seja exigido por lei.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nPara acessar os recursos de m\u00eddia da BeOne, visite nosso <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beonemedicines.com%2Fnewsroom&amp;esheet=54539621&amp;newsitemid=20260521387982&amp;lan=pt-BR&amp;anchor=Site+de+not%26iacute%3Bcias&amp;index=15&amp;md5=876b1e9bd5bcadead43babf71d0ab167\" rel=\"follow\" shape=\"rect\" target=\"_blank\"><b>Site de not\u00edcias<\/b><\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p>\n____________________<br \/>\n<br \/><sup>1<\/sup> ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260521387982\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260521387982\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p><b>Contato para investidores<br \/>\n<\/b><\/p>\n<p>Liza Heapes\n<\/p>\n<p>+1 857-302-5663\n<\/p>\n<p><a href=\"mailto:ir@beonemed.com\" rel=\"follow\" shape=\"rect\">ir@beonemed.com<\/a><\/p>\n<p><b>Contato para a m\u00eddia<br \/>\n<\/b><\/p>\n<p>Kyle Blankenship\n<\/p>\n<p>+1 667-351-5176\n<\/p>\n<p><a href=\"mailto:media@beonemed.com\" rel=\"follow\" shape=\"rect\">media@beonemed.com<\/a><\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank'>BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/331593?partnerId=4593' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Evid\u00eancias de longo prazo e do mundo real refor\u00e7am o BRUKINSA como base do tratamento da LLCTr\u00eas apresenta\u00e7\u00f5es orais na ASCO destacam a r\u00e1pida acelera\u00e7\u00e3o do pipeline de tumores s\u00f3lidos da BeOne<\/p>","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[315],"tags":[337,324,352],"class_list":["post-23906","post","type-post","status-publish","format-standard","category-noticias-corporativas-dino","tag-entretenimento","tag-negocios","tag-saude-e-bem-estar"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angelboss.com.br\/en\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\" \/>\n<meta property=\"og:description\" content=\"Evid\u00eancias de longo prazo e do mundo real refor\u00e7am o BRUKINSA como base do tratamento da LLCTr\u00eas apresenta\u00e7\u00f5es orais na ASCO destacam a r\u00e1pida acelera\u00e7\u00e3o do pipeline de tumores s\u00f3lidos da BeOne\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angelboss.com.br\/en\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/\" \/>\n<meta property=\"og:site_name\" content=\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"36 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/person\\\/b6676b8d991f97199ef2d5b8e5c2d8a5\"},\"headline\":\"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos\",\"datePublished\":\"2026-05-22T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/\"},\"wordCount\":7176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\",\"keywords\":[\"ENTRETENIMENTO\",\"NEG\u00d3CIOS\",\"SA\u00daDE E BEM-ESTAR\"],\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/\",\"name\":\"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\",\"datePublished\":\"2026-05-22T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/2026\\\/05\\\/22\\\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/angelboss.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#website\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/\",\"name\":\"Portal Masculino de Moda, Beleza, Luxo e Business - Angel Boss\",\"description\":\"O Maior Portal sobre Moda, Luxo, Beleza e Business Masculino do Brasil\",\"publisher\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\"},\"alternateName\":\"Maior Portal e Blog de Beleza Masculina e Luxo\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/angelboss.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#organization\",\"name\":\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/angelboss.com.br\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg\",\"contentUrl\":\"https:\\\/\\\/angelboss.com.br\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg\",\"width\":1280,\"height\":1280,\"caption\":\"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss\"},\"image\":{\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/angelboss.com.br\\\/#\\\/schema\\\/person\\\/b6676b8d991f97199ef2d5b8e5c2d8a5\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/angelboss.com.br\\\/en\\\/author\\\/DINO\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angelboss.com.br\/en\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","og_description":"Evid\u00eancias de longo prazo e do mundo real refor\u00e7am o BRUKINSA como base do tratamento da LLCTr\u00eas apresenta\u00e7\u00f5es orais na ASCO destacam a r\u00e1pida acelera\u00e7\u00e3o do pipeline de tumores s\u00f3lidos da BeOne","og_url":"https:\/\/angelboss.com.br\/en\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/","og_site_name":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","article_published_time":"2026-05-22T00:00:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Written by":"DINO","Est. reading time":"36 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#article","isPartOf":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/"},"author":{"name":"DINO","@id":"https:\/\/angelboss.com.br\/#\/schema\/person\/b6676b8d991f97199ef2d5b8e5c2d8a5"},"headline":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos","datePublished":"2026-05-22T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/"},"wordCount":7176,"commentCount":0,"publisher":{"@id":"https:\/\/angelboss.com.br\/#organization"},"image":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp","keywords":["ENTRETENIMENTO","NEG\u00d3CIOS","SA\u00daDE E BEM-ESTAR"],"articleSection":["Not\u00edcias Corporativas"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/","url":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/","name":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos - Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","isPartOf":{"@id":"https:\/\/angelboss.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#primaryimage"},"image":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp","datePublished":"2026-05-22T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260521387982r1&amp;sid=brdno&amp;distro=ftp"},{"@type":"BreadcrumbList","@id":"https:\/\/angelboss.com.br\/2026\/05\/22\/331593-beone-medicines-lidera-o-setor-de-oncologia-na-asco-e-na-eha-2026-com-mais-de-60-resumos-cientificos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/angelboss.com.br\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos cient\u00edficos"}]},{"@type":"WebSite","@id":"https:\/\/angelboss.com.br\/#website","url":"https:\/\/angelboss.com.br\/","name":"Portal Masculino de Moda, Beleza, Luxo e Business - Angel Boss","description":"O Maior Portal sobre Moda, Luxo, Beleza e Business Masculino do Brasil","publisher":{"@id":"https:\/\/angelboss.com.br\/#organization"},"alternateName":"Maior Portal e Blog de Beleza Masculina e Luxo","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angelboss.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/angelboss.com.br\/#organization","name":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss","url":"https:\/\/angelboss.com.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/angelboss.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/angelboss.com.br\/wp-content\/uploads\/2025\/12\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg","contentUrl":"https:\/\/angelboss.com.br\/wp-content\/uploads\/2025\/12\/WhatsApp-Image-2025-12-11-at-12.54.26.jpeg","width":1280,"height":1280,"caption":"Portal Masculino de Moda, Beleza, Luxo and Business - Angel Boss"},"image":{"@id":"https:\/\/angelboss.com.br\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/angelboss.com.br\/#\/schema\/person\/b6676b8d991f97199ef2d5b8e5c2d8a5","name":"DINO","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f29568383aedf96da155b6f87103b0e04b1c662f982055cda25086444ab33ff8?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/angelboss.com.br\/en\/author\/DINO\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts\/23906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/comments?post=23906"}],"version-history":[{"count":0,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/posts\/23906\/revisions"}],"wp:attachment":[{"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/media?parent=23906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/categories?post=23906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angelboss.com.br\/en\/wp-json\/wp\/v2\/tags?post=23906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}